TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million Series A+ financing round. The round was led by Qingdao Guoxin, with existing shareholders Baino Capital, Han Kang Capital, and Beta Fund continuing to add investments. Kaicheng Capital once again served as the exclusive financial advisor. The funds raised in this round will primarily be used to accelerate the research and development, clinical studies, and commercialization efforts of multiple drugs targeting the aromatic hydrocarbon receptor (AhR) for the treatment of various autoimmune inflammatory diseases.
TheDerma specializes in the development of drugs targeting the AhR, a “super target” expressed in various human tissues, particularly in the epidermis and mucosal tissues. Diseases related to the AhR target cover areas such as the digestive system, respiratory system, ophthalmology, and dermatology.
Dr. Chen Genhui, CEO of TheDerma, is the co-inventor of the world’s first topical new drug targeting the AhR. He has led the drug from its discovery, through clinical trials, to industrialization and registration for market launch. The drug has been approved and launched in both China and the United States, marking the first time an original research topical new drug was launched domestically before overseas.- Flcube.com
